Group leader: Philippe Millet
Group name: PET and SPECT Quantification
The research projects of our group focus on various themes of neuroimaging including: 1- Development of quantitative imaging methods in PET/SPECT for the study of different cerebral neurotransmission systems (kinetic modeling of dopaminergic (D2/3) and serotonergic (5-HT2A) neurotransmission), neuroinflammation using various PET/SPECT TSPO tracers (18kDa Translocator Protein). 2- pPreclinical PET/SPECT applications: study of the mechanism of action of atypical antipsychotics (SNF n¡156829); In vivo study of rodent neuroinflammation with the use of adenoviral vector-mediated protein overexpression and a TSPO deficient mouse model; Study of neuroinflammation in relation to amyloid deposits and behavioral and cognitive alterations in transgenic models of Alzheimer's disease (collaboration: Dr Benjamin Tournier, firstname.lastname@example.org). 3- in vitro studies on the post-mortem human brain for the identification and characterization of inflammation with respect to neurodegenerative pathologies. 4- clinical applications, particularly study of neuroinflammatory process in various psychiatric pathologies (project under development) (collaborations: Dr Stergios Tsartsalis, email@example.com; Dr Benjamin Tournier, firstname.lastname@example.org). 5- development of SPECT / PET radioligands in collaboration with the CERMN (Center for Studies and Research on the Medicine of Normandy, Caen, http://cermn.unicaen.fr/) and ANSTO (Australian Nuclear Science and Technology Organization, http://www.ansto.gov.au/ResearchHub/).